Why Women on GLP-1 Weight Loss Drugs Are Losing Hair: The Science Explained.
Graham Phillips
FRPharmS • Founder
CAUTION: please read my earlier post first. This one is long, complicated and hard work. Below is my attempt to compile the best current evidence to explain why women on GLP-1–based weight-loss drugs are shedding hair.
Hair loss came up in the trials, especially for tirzepatide (Mounjaro/Zepbound) and it skews female. For example in the Zepbound (tirzepatide) obesity trials, “Hair loss” occurred in 4–5% of those taking the drugs vs 1% on placebo” The US label explicitly notes hair loss was associated with weight reduction and was more frequent in females (7.1%) than males (0.5%).
In Wegovy (semaglutide 2.4 mg) adult obesity trials, hair loss occurred in 3% vs 1% on placebo. Worryingly in adolescents it was higher at 4% vs 0%.
Dermatology literature recognises sudden weight loss or reduced protein intake as classic triggers of what is termed Telogen Effluvium (diffuse hair shedding 2–3 months after the trigger).
Why women more than men?
Likely due to a mix of higher baseline iron deficiency in menstruating women (iron deficiency and low ferritin are associated with Telogen Effluvium) and in addition where the female hormones are disrupted (eg PCOS) that can also exacerbate female hair loss during weight-change and there’s greater shedding with longer hair.
It’s generally accepted that lower ferritin (iron) levels are associated with TE. For this reason, dermatologists target ferritin levels above 40–70 μg/L when treating diffuse shedding.
Could GLP-1 drugs act directly on hair follicles?
Probably not! Interestingly GLP-1 receptors have been shown in the hair follicles and keratinocytes of mice! And GLP-1 signalling does modulate skin biology. But it’s by no means clear that this can be applied in humans.. or to put it another way the weight-loss/undernutrition explanation still fits best.
So What’s the solution?
Slow the rate of weight loss and protect nutrition:
Aim to lose ~0.5–1.0 kg/week (NHS/NICE/BHF guidance) Faster loss increases risk for gallstones as well as malnutrition, and, of course, TE.
Protein: during energy deficit, intakes around 1.5g/kg/day help preserve lean mass and reduce “undernutrition” signalling. So for a 60kg woman, aim to eat around 100g of protein each day, ideally spread across every meal. This should lower TE risk because low protein intake is a recognised TE trigger.
Micronutrients: check and correct for iron (ferritin); B12/folate; vitamin D, and possibly zinc, especially if appetite is low or vomiting occurs. Low ferritin is associated with TE. In practice targets often used in dermatology are ≥40 μg/L if otherwise healthy, and ≥70 μg/L if inflammation is present. (NB: These thresholds are consensus-based, not proven by an RCT).
If nausea and/or early satiety from GLP is limiting food intake, treat with, for example anti-emetics) so you can meet protein and micronutrient needs. However my approach would be reduce the dose of GLP to the absolute minimum to tone down the food noise, and consider spacing out the doses every 10-14 days or maybe even longer.
Adjust the GLP-1 regimen if shedding is significant.
Because the tirzepatide label links hair loss to weight reduction, consider slowing dose escalation, reducing the dose, or pausing to stabilise weight while correcting nutrition. (None of the trials specifically test this for hair. Its pretty-much common sense).
Confirm the diagnosis: it’s crucially important not to jump to conclusions. Don’t miss other causes eg hypo-throid / hashimotos.
Ask your clinician to rule out: thyroid disease, iron deficiency, postpartum TE, Female Pattern Hair Loss, alopecia areata (there have been rare case reports after semaglutide) and drug-induced causes. TE typically starts 2–3 months after the trigger and improves once the trigger is controlled. This is a key diagnostic.
Suggested baseline labs for a female patient, on a GLP-1RA, with new diffuse shedding:
Full Blood Count; ferritin ± iron studies; TSH in all cases; B12/folate, vitamin D, and zinc if diet is restricted or there are risk factors. Also consider androgen profile if there’s pattern thinning suggestive of FPHL/PCOS.
Time and supportive therapies for hair
Reassuraningly acute TE is self-limited. Once weight and nutrition stabilise, shedding usually settles over a 3–6 month period, with hair density returning over the ensuing 6–12+ months.
Topical minoxidil can be considered to speed recovery. Evidence for minoxidil in TE is limited but suggests earlier improvement, and it’s widely used by dermatologists. Oral minoxidil has evidence in FPHL specifically, but there’s limited data in the case of TE.
Putting it all together: A Pragmatic plan you can act on now…
Check for TE & rule-out other potential diagnoses. History (ie onset 2–3 months after major weight-loss) Order labs (CBC, ferritin, TSH, etc as described above).
Nutrition: Aim for at least 1.5g/kg/day protein. Eat regular meals, Correct iron if ferritin is low.
Slow the rate of weight loss: aim for 0.5–1.0 kg/week loss. If shedding worsens, consider stepping down the dose or even pausing while fixing nutrition and monitoring weight.
Support the scalp: optional topical minoxidil 5% after review by a specialist. Also gentle hair care and obviously avoid crash dieting.
Reassess at 12–16 weeks: shedding usually eases as food intake and weight stabilise. If not, or if FPHL pattern thinning appears, refer to dermatology
Lab Checklist for Hair Loss on GLP-1 Therapy
- 1. General Screening
- Full Blood Count (FBC / CBC) to detect anaemia (esp. iron-deficiency or chronic disease).
- Ferritin – key marker of iron stores. Dermatologists often aim for ≥40–70 µg/L depending on inflammation status for hair regrowth.
- Thyroid Function Tests (TSH, ± Free T4/T3) – hypothyroidism and hyperthyroidism both cause diffuse shedding.
- Urea & Electrolytes / Basic Metabolic Panel – to check overall nutritional/metabolic status (dehydration, renal function).
- 2. Nutritional & Vitamin Deficiencies
- Vitamin B12 and Folate – low levels linked with diffuse hair shedding and fatigue.
- Vitamin D (25-OH vitamin D) - deficiency associated with both TE and FPHL.
- Zinc – deficiency is uncommon but documented in diffuse alopecia.
- Albumin / Prealbumin – low levels can suggest inadequate protein intake (esp. in rapid weight loss).
- 3. Female Hormonal Profile (if pattern thinning or other risk factors)
- Serum Androgens:
- Total and Free Testosterone
- Sex Hormone Binding Globulin (SHBG)
- DHEAS (if PCOS or adrenal cause suspected)
- LH, FSH, ± Prolactin – if menstrual irregularities or PCOS suspected.
- Oestradiol – may be useful if perimenopausal/menopausal status uncertain.
- Specialist Tests (case-by-case)
- ANA / Autoimmune screen – if alopecia areata suspected.
- Copper & Selenium – rare, usually only in unexplained refractory cases.
- CRP / ESR – to interpret ferritin correctly (raised inflammation can falsely elevate ferritin).
- Baseline “core” labs (everyone with GLP-1 hair loss):
- FBC, Ferritin, TSH, Vitamin B12, Folate, Vitamin D, Zinc, U&E/renal panel, Albumin.
If diffuse shedding is confirmed and ferritin <40–70 µg/L; Correct iron deficiency with supplementation.
Recheck in 3–6 months.
If hair loss looks patterned (crown/part-line widening):
Add full hormonal panel (Testosterone, SHBG, DHEAS, LH/FSH, ± Prolactin).
If diagnosis uncertain or severe:
Consider autoimmune screen, scalp biopsy, or dermatology referral.
Most women on GLP-1 drugs who shed hair are experiencing telogen effluvium triggered by rapid weight loss and nutritional shortfall. The labs above help confirm the diagnosis, rule out thyroid/iron/hormonal causes, and guide targeted supplementation (iron, B12, vitamin D, zinc, protein). With correction and stabilisation, regrowth is usually seen within 6–12 months.
About Graham Phillips
Graham Phillips is a registered pharmacist (FRPharmS) with over 35 years of experience. Frustrated by “pill for every ill” medicine, he founded ProLongevity to help people reverse chronic disease and lose weight through precision lifestyle medicine.
Read more
The GLP-1 Weight Loss Diet
What should you eat while taking Mounjaro, Wegovy or Foundayo? A practical, guide to protein, muscle preservation, carbohydrates, GI side effects and keeping the weight off.
The Complete Guide to GLP-1 Medicines for Type2 Diabetes
GLP-1 based drugs such as Mounjaro® (tirzepatide) and Ozempic® (semaglutide) have transformed the treatment of Type 2 diabetes. For many people they represent a genuine turning point.
But here’s the key question:
Foundayo (Orforglipron): The New UK Weight-Loss Pill – Is It Really a ‘Treatment for Life’?
A new daily GLP-1 weight-loss pill has been approved in the UK. Some headlines are already calling it a potential “treatment for life”. Foundayo clearly works but the science does not yet tell us that everyone who starts it will stay on it, or need it, for life.